Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: Randomized comparison of direct observed therapy and self-administration

American Journal of Gastroenterology

Volumn 103, Issue 11, 2008, Pages 2757-2765

  Bonkovsky, Herbert L ^a,h   Tice, Alan D ^b   Yapp, Rockford G ^c   Bodenheimer Jr , Henry C ^d   Monto, Alexander ^e   Rossi, Stephen J ^f   Sulkowski, Mark S ^g  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c Advocate Good Samaritan Hospital   (United States)

^d BETH ISRAEL MEDICAL CENTER   (United States)

^e SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f HOFFMANN LA ROCHE INC   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h CAROLINAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; DIRECTLY OBSERVED THERAPY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; METHADONE; MIDDLE AGED; NARCOTICS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; SELF ADMINISTRATION; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 55349144862     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2008.02065.x     Document Type: Article

References (47)

1. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997 26 (Suppl 1 62S 5S.
2. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002 36 : S93 S8.
3. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006 144 : 705 14.
4. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995 74 : 212 20.
5. Lorvick J, Kral AH, Seal K, et al. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health 2001 91 : 46 7.
6. Des Jarlais DC, Schuchat A. Hepatitis C among drug users: Déjà vu all over again? Am J Public Health 2001 91 : 21 2.
7. Hallinan R, Byrne A, Amin J, et al. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. J Gastroenterol Hepatol 2005 20 : 1082 6.
8. Lindenburg K, Weegink C, Schinkel J, et al. Hepatitis C screening and treatment among drug users in Amsterdam: Interim results of the inclusion procedure in the Dutch C project abstract Hepatology 2006 44 : 329A.
9. Manns MP, McHutchison JG, Gordon SC, et al., and the International Hepatitis Interventional Therapy Group. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001 358 : 958 65.
10. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 82.
11. Hadziyannis SJ, Sette HJr, Morgan TR, et al., for the PEGASYS International Study Group. Peginterferon-a2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 55.
12. National Institutes of Health. Management of hepatitis C: 2002. NIH Consens Statement 2002 19 : 1 46.
13. Walley AY, White MC, Kushel MB, et al. Knowledge of and interest in hepatitis C treatment at a methadone clinic. J Subst Abuse Treat 2005 28 : 181 7.
14. Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: Knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend 2001 61 : 211 5.
15. Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users N Engl J Med 2001 345 : 211 5.
16. Weaver MF, Cropsey KL, Fox SA. HCV prevalence in methadone maintenance: Self-report versus serum test. Am J Health Behav 2005 29 : 387 94.
17. Sylvestre DL, Litwin AH, Clements BJ, et al. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005 29 : 159 65.
18. Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003 98 : 2281 8.
19. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003 37 : 443 51.
20. Mauss S, Berger F, Goelz J, et al. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004 40 : 120 4.
21. Sulkowski M, Wright T, Rossi S, et al. Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. Clin Pharmacol Ther 2005 77 : 214 24.
22. O'Connor PG, Molde S, Henry S, et al. Human immunodeficiency virus infection in intravenous drug users: A model for primary care. Am J Med 1992 93 : 382 6.
23. Umbricht-Schneiter A, Ginn DH, Pabst KM, et al. Providing medical care to methadone clinic patients: Referral versus on-site care. Am J Public Health 1994 84 : 207 10.
24. Chaulk CP, Moore-Rice K, Rizzo R, et al. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995 274 : 945 51.
25. Gourevitch MN, Wasserman W, Panero MS, et al. Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. J Addict Dis 1996 15 : 93 104.
26. Weisner C, Mertens J, Parthasarathy S, et al. Integrating primary medical care with addiction treatment: A randomized controlled trial. JAMA 2001 286 : 1715 23.
27. Sylvestre D, Smith A, Barrett L, et al. Integrated drug and HCV treatment for street-recruited heroin users abstract Hepatology 2006 44 : 221A.
28. Beck AT, Steer RA, Brown GK. Beck Depression Inventory-II (BDI-II), 2nd Ed. San Antonio, TX : Harcourt Assessment, 1996.
29. Bayliss MS, Gandek B, Bungay KM, et al. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998 7 : 39 55.
30. Ware JE Jr., Bayliss MS, Mannocchia M, et al. Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999 30 : 550 5.
31. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: An interim analysis. Drug Alcohol Depend 2002 67 : 117 23.
32. Hueppe D, Zehnter E, Manns MP, et al. Treatment with peginterferon alfa 2b and ribavirin of chronic hepatitis C patients on substitution therapy and outcome in the clinical setting in Germany abstract Hepatology 2006 44 : 338A.
33. Simonova M, Katzarov K, Takov D, et al. Therapeutic efficacy of 24 weeks' antiviral treatment in addicted patients on methadone maintenance therapy who have chronic hepatitis C, genotype 1, with low baseline viremia abstract Hepatology 2006 44 : 326A.
34. Hussaini H, Cole E, Flynn A, et al. Substitute opiate use in intravenous drug users (IVDUs) does not adversely effect sustained virological response (SVR) following treatment of chronic hepatitis C (CHC) with pegylated interferon alpha (PEG- IFN) and ribavirin abstract Hepatology 2006 44 : 339A.
35. Brigada R, Bonasso M, Borroni G, et al. Overcoming barriers to treatment of hepatitis C in Italian drug users. The importance of a co-management model of care abstract Hepatology 2006 44 : 330A.
36. Raptopoulou M, Lalla T, Sinakos E, et al. Treatment of intravenous drug users (IVDU) with chronic Hepatitis C: Treatment response, compliance and side effects abstract J Hepatol 2006 44 : S223.
37. Zehnter E, Mauss S, John C, et al. Treatment of chronic hepatitis C with peginterferon alfa-2a (40 KD) and ribavirin in patients with or without drug use abstract Gastroenterology 2006 130 : A-840.
38. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002 7 : 942 7.
39. Bonkovsky HL, Woolley JM, and The Consensus Interferon Study Group. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999 29 : 264 70.
40. Hussain KB, Fontana RJ, Moyer CA, et al. Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. Am J Gastroenterol 2001 96 : 2737 44.
41. Fontana RJ, Moyer CA, Sonnad S, et al. Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. Am J Gastroenterol 2001 96 : 170 8.
42. McHutchison JG, Ware JE Jr., Bayliss MS, et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001 34 : 140 7.
43. Bonkovsky HL, Snow KK, Malet PF, et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 2007 46 : 420 31.
44. Neary MP, Cort S, Bayliss MS, et al. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis 1999 19 (Suppl 1 77 85.
45. Farley JD, Al-Khafaji Y, Mikami T, et al. Re-infection following successful treatment for hepatitis C virus Infection with either alpha interferon or pegylated interferon/ribavirin combination therapy abstract Hepatology 2006 44 : 325A.
46. Strauss SM, Astone-Twerell JM, Munoz-Plaza C, et al. Hepatitis C knowledge among staff in U.S. drug treatment programs. J Drug Educ 2006 36 : 141 58.
47. Astone JM, Strauss SM, Hagan H, et al. Outpatient drug treatment program directors' hepatitis C-related beliefs and their relationship to the provision of HCV services. Am J Drug Alcohol Abuse 2004 30 : 783 97.